[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasms-endometrial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasms-endometrial":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,76,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100614956","phase-3-a-study-to-investigate-mocertatug-rezetecan-compared-with-chemotherapy-in-participants-with-endometrial-cancer-after-platinum-based-chemotherapy-and-immunotherapy-behold-endometrial01-100614956",false,"NCT07286331","A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n* Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF).\n* Has histologically confirmed endometrial carcinoma including but not limited to endometroid, serous, clear cell, and endometrial carcinosarcoma. Mixed epithelial carcinomas are permitted.\n* Has undergone at least 1 and no more than 2 lines of prior systemic treatment for EC. Up to 3 lines of prior systemic treatment are acceptable if one line was administered in the adjuvant\u002Fneo-adjuvant setting. The definition of prior lines of therapy is as follows:\n\n  * Adjuvant ± neo-adjuvant therapy counts as one line of treatment.\n  * Maintenance therapy is considered part of the preceding line and does not count as an independent line.\n  * Switching to another agent within the same class due to toxicity (without disease progression) is considered part of the same line of therapy.\n  * Unplanned addition or switching to a new anti-cancer therapy in a different class is considered a separate line of therapy.\n  * Hormonal therapy is NOT counted as a separate line.\n* Must have progressed on or after prior platinum-based chemotherapy and have received anti- Programmed cell death 1 (PD-1) \u002Fanti- Programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination. Participants deemed unsuitable for a prior PD-1\u002FPD-L1 inhibitor therapy (contraindications such as immunodeficiency, autoimmune disease that required systemic treatment) as determined by the investigator or treating physician are eligible.\n* Participants must have a platinum-free interval of less than 12 months if they previously received platinum-based therapy solely in the adjuvant setting. The platinum-free interval is defined as the date of the last dose of platinum-based chemotherapy to the date of disease progression.\n\n  * If PD-L1\u002FPD-1 inhibitor therapy was administered with platinum-based treatment, participant is eligible regardless of whether the Platinum-free interval (PFI) exceeds 12 months.\n  * Participants with metastatic disease who underwent treatment including gynecological surgery followed by a platinum-based regimen, or those deemed intolerant to platinum-based therapy, are eligible regardless of whether the PFI exceeds 12 months.\n* Has provided a Formalin-fixed, paraffin-embedded (FFPE) tumor tissue sample sufficient for the central assessment of B7 homolog 4 protein (B7-H4) expression, with the result of B7-H4 expression testing available prior to date of randomization.\n* Has ≥1 Target Lesion per RECIST 1.1 by BICR eligibility review of screening scans.\n* Is willing to use adequate contraception. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and 1 of the following conditions applies:\n\n  * Is a Participant of non-childbearing potential (PONCBP) OR\n  * Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, 30 days prior to Cycle 1 Day 1 (C1D1) and during the study intervention period and for at least 8 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.\n* A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention\n\n  * If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n  * Additional requirements for pregnancy testing during and after study intervention are described in protocol.\n  * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a participant with an early undetected pregnancy.\n* Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and in the protocol.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has adequate organ function.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Mesenchymal tumors of the uterus (uterine sarcomas) and neuroendocrine uterine cancer.\n* Has a malignancy (except disease under study) that has progressed or required active treatment within the past 36 months prior to date of randomization except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \\[e.g., breast, cervix, bladder\\] that have been resected with no evidence of metastatic disease, or that is otherwise considered cured by the investigator.\n* Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.\n* Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.\n* Has untreated brain or Central nervous system (CNS) metastases or brain\u002FCNS metastases that have progressed (e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain\u002FCNS metastases). Participants with previously treated and clinically stable brain\u002FCNS metastases and who have completed all corticosteroid therapy for ≥14 days before date of C1D1 are not excluded from participation.\n* Has any evidence of current Interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis.\n* Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤ Grade 1 or to the baseline status preceding prior therapy, excluding alopecia, hearing loss, vitiligo and endocrinopathy managed with replacement therapy, or that the investigator, with the agreement of the sponsor, considers to be stable or not clinically relevant for the tolerability of study intervention in the current clinical study.\n* Has any serious and\u002For unstable medical condition (including infection) or any serious and\u002For unstable psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.\n* Has had any major surgery within 28 days prior to date of C1D1 or history of local radiotherapy within 21 days prior to C1D1.\n* Has received treatment with an investigational agent within 30 days prior to C1D1.\n* Has received prior therapy with Topo1i (e.g. irinotecan or topotecan) or ADC with a Topo1i payload, or B7-H4 targeted therapy.\n* Has received treatment with any cytotoxic chemotherapy drugs or other antitumor drugs (including endocrine therapy, molecular targeted therapy, immunotherapy, biotherapy and investigational drug) within 30 days or 5 half-lives, whichever is shorter, prior to C1D1; or need to continue these drugs during the study.\n* Has received any live vaccine within 30 days prior to C1D1.Note: mRNA and adenoviral-based Coronavirus disease 2019 (COVID-19) vaccines are considered non-live.\n* Has received treatment with inhibitors of P-glycoprotein (P-gp), Breast cancer resistant protein (BCRP), or OATP1B1\u002F1B3 transporters within 7 days prior to first dose of study drug. P-gp inducers should be discontinued for at least 14 days before the start of the study drug.\n* Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony stimulating factor (G-CSF), Granulocyte-macrophage colony stimulating factor (GM-CSF), or recombinant erythropoietin) within 14 days prior to C1D1.\n* Has a known Human immunodeficiency virus (HIV) infection AND meets at least 1 of the following criteria:\n\n  * Has documented evidence of plasma HIV-1 Ribonucleic acid (RNA) ≥50 c\u002FmL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV1 RNA levels consistently \\\u003C50 c\u002FmL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c\u002FmL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR\n  * Has not had Cluster of differentiation (CD)4 cell counts measured in the past 12 months (i.e., at least 2 separate measurements taken a minimum of 28 days apart, 1 of which must be conducted at screening); OR\n  * Has had any CD4 cell count values ≤350 cells\u002Fmm3 in the past 12 months. OR\n  * Has had 1 or more changes in their combination antiretroviral therapy regimen or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR\n  * Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR\n  * Has received treatment with an HIV1 immunotherapeutic vaccine within 90 days prior to screening.\n* Has an Alanine aminotransferase (ALT) value \\>2.5× Upper limit of normal (ULN) and\u002For for participants documented liver metastases\u002Ftumor infiltration has an ALT value \\>5x ULN\n* Has a total bilirubin value \\>1.5x ULN.\n* Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal\u002Fgastric varices, or persistent jaundice.\n* Has documented presence of Hepatitis B surface antigen (HBsAg) and\u002For Hepatitis B core antibody (HBcAb) at screening unless they meet both the following criteria:\n\n  * Participants with chronic Hepatitis B virus (HBV) infection (HBsAg+) or positive HBcAb are required to be receiving effective antiviral therapy (i.e., with nucleos(t)ide analogs \\[Tenofovir or Entecavir\\]) for at least 14 days prior to C1D1 and are willing to continue for at least 6 months after treatment discontinuation or longer at the discretion of the treating hepatologist.\n  * HBV Deoxyribonucleic acid (DNA) must be adequately suppressed, as per institutional or local guidelines, prior to initiation of study intervention.\n* Has a positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to C1D1 unless HCV RNA is negative, indicating past resolved HCV infection, including participants who have undergone curative treatment.\n* Has a positive HCV RNA test result at screening or within 3 months prior to C1D1.\n* Has QTc \\>470 milliseconds (msec)\n* Has a history within 12 months prior to screening of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure \\[NYHA 1994\\], or clinically significant arrhythmia not controlled by standard of care therapy.\n* Has Left ventricular ejection fraction (LVEF) \\\u003C50% or less than institutional lower limit of normal.\n* Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).","FEMALE","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.",[26],"Neoplasms, Endometrial",[28,29,30,31,32,33,34,35],"Endometrial Cancer","Mocertatug rezetecan","Mo-Rez","GSK5733584","Paclitaxel","Doxorubicin","Antibody-drug conjugate","BEHOLD-Endometrial01","RECRUITING","2026-07-01",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-06-04",{"date":44,"type":20},"2029-05-30",{"name":46,"class":47},"GlaxoSmithKline","INDUSTRY",14,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100642161","phase-4-a-study-to-evaluate-the-safety-of-dostarlimab-in-adult-participants-in-india-with-primary-advanced-or-recurrent-endometrial-cancer-100642161","NCT07652515","A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer","Phase 4, Open Label, Single-arm, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Primary Advanced or Recurrent Endometrial Cancer","Inclusion Criteria:\n\n* Participant with greater than or equals to (\\>=) 18 years of age, at the time of signing the informed consent.\n* Participant has histologically or cytologically proven EC with recurrent or advanced disease.\n* Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination based on investigator's assessment.\n* Eligible for dostarlimab treatment according to the approved prescribing information and the investigator's clinical judgement.\n* Woman of childbearing potential (WOCBP) agrees to use contraceptive from screening through at least 180 days after the last dose.\n* Negative urine pregnancy test at most 24 hours prior to the first dose of study intervention.\n* Capable of giving signed informed consent.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Participant has had greater than (\\>) 1 recurrence of endometrial cancer.\n* Participant has a concomitant malignancy, or participant has a prior non endometrial invasive malignancy who has been disease-free for less than (\\\u003C) 3 years or who received any active treatment in the last 3 years for that malignancy.\n* Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.\n* Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy.\n* Participant has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.\n* Participant has not recovered (i.e., to Grade less than or equal to \\[\\\u003C=\\] 1 or to Baseline) from cytotoxic therapy induced AEs or has received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor \\[G-CSF\\], Granulocyte macrophage colony-stimulating factor \\[GM-CSF\\], or recombinant erythropoietin) within 21 days prior to the first dose of study drug.\n* Either the history of hypersensitivity to excipients of the study intervention or to drugs with a similar chemical structure or class of the study intervention.\n* Participant has known active hepatitis B (e.g., hepatitis B surface antigen reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid \\[qualitative\\] is detected).\n* Participant has received neo-adjuvant\u002Fadjuvant systemic anticancer therapy for primary Stage III or IV disease and:\n\n  * has not had a recurrence or Progressive disease (PD) prior to first dose on the study, or\n  * has had a recurrence or PD within 6 months of completing systemic anticancer therapy treatment prior to first dose on the study.\n* Participant has received prior therapy with an anti- Programmed death protein 1 (anti-PD-1), anti- Programmed death ligand 1 (anti-PD-L1), or Programmed death ligand 2 (anti PD L2) agent.\n* Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days or \\\u003C5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.\n* Systemic glucocorticoids for any purpose other than to manage symptoms of suspected irAEs. If medically deemed necessary (e.g., acute asthma or chronic obstructive pulmonary disease exacerbation, prophylaxis for intravenous (IV) contrast if indicated), Investigators are allowed to use their judgment to treat participants with systemic steroids. In such cases, systemic steroids should be stopped at least 24 hours prior to the next dose of study treatment.\n* Participant has received, or is scheduled to receive, a live vaccine within 30 days before first dose of study intervention, during study treatment, and for up to 180 days after receiving the last dose of study intervention.\n* Participant has a diagnosis of immunodeficiency and is receiving systemic steroid therapy (\\>10 milligrams \\[mg\\] daily prednisone or equivalent) within 7 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication.\n* Participant is currently receiving study intervention, or is enrolled or has participated in any other clinical study involving an investigational intervention and received investigational treatment or used an investigational device within 4 weeks of the first dose of dostarlimab.\n* Participant is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study intervention.\n* Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.",{"count":57,"type":20},100,[59],"PHASE4","This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).",[26],[63,64,65,66,32],"Carboplatin","Dostarlimab","Endometrial cancer","First line treatment","NOT_YET_RECRUITING","2026-06-11",{"date":70,"type":40},"2026-06-17",{"date":72,"type":20},"2026-08-17",{"date":74,"type":20},"2030-08-30",{"name":46,"class":47},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100601267","phase-2-a-study-of-dostarlimab-in-combination-with-carboplatin-paclitaxel-in-chinese-participants-with-primary-advanced-or-recurrent-endometrial-cancer-ec-100601267","NCT07108270","A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Participants With dMMR\u002FMSI-H Primary Advanced or Recurrent Endometrial Cancer in China (China RUBY)","Inclusion Criteria:\n\n1. Participant has histologically or cytologically proven EC with recurrent or advanced disease.\n2. Participant has molecular subtype of defective mismatch repair (dMMR) or microsatellite instability high (MSI-H) determined by the central reference laboratory before study intervention.\n3. Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination, and presence of at least one target lesion per RECIST 1.1 based on Investigator's assessment and meet at least 1 of the following criteria:\n\n   1. Has primary Stage III to IV disease and is naive to systemic anticancer therapy for EC;\n   2. Has first recurrent disease and is naïve to systemic anticancer therapy for EC;\n   3. Had received prior neo-adjuvant\u002Fadjuvant anticancer therapy and had a recurrence or PD ≥6 months after completing treatment (first recurrence only).\n4. Participant has adequate archive tumor tissue sample for MMR\u002FMSI status testing. If no archival tissue is available, tissue sample must be obtained before study intervention.\n5. Participant is not pregnant or breastfeeding and agrees to use a highly effective contraceptive method during the study period if a woman of childbearing potential (WOCBP).\n6. Participant has an Eastern Cooperative Oncology Group Performance status (ECOG PS) of 0 or 1.\n7. Participant has adequate organ function, as assessed by hematologic, renal, hepatic and coagulation parameters.\n\nExclusion Criteria:\n\n1. Participant has a concomitant malignancy, or participant has a prior non-endometrial invasive malignancy who has been disease-free for \\\u003C3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.\n2. Participant has any medical history of interstitial lung disease or pneumonitis.\n3. Participant has cirrhosis or current unstable liver or biliary disease.\n4. Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.\n5. Participant has a diagnosis of immunodeficiency.\n6. Participant has received prior therapy with an anti- Programmed death protein 1 (PD-1), anti- Programmed death ligand 1 (PD-L1), anti- Programmed death ligand 2 (PD-L2), or anti- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent.\n7. Participant has not recovered adequately from AEs.\n8. Participant has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days prior to the first dose of study intervention.\n9. Participant has received any live vaccine within 30 days of the first dose of study intervention. Vaccination against coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms are not exclusionary.\n10. Participant has Hepatitis B surface antigen (HBsAg) positive, or Hepatitis C virus (HCV) Ribonucleic acid (RNA) positive at screening or within 3 months prior to the first dose of study intervention.\n11. Participant is known human immunodeficiency virus (HIV) infection.\n12. Participant is currently participating and receiving study intervention or has participated in a study of an investigational agent and received study intervention or used an investigational device within 4 weeks of the first dose of treatment.\n13. Participant with contraindication to carboplatin and paclitaxel.",{"count":84,"type":20},30,[86],"PHASE2","The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.",[26],[65,64,63,32],"2025-12-19",{"date":92,"type":40},"2025-12-22",{"date":94,"type":40},"2025-11-27",{"date":96,"type":20},"2030-03-31",{"name":46,"class":47},1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100585066","phase-4-a-study-to-evaluate-the-safety-of-dostarlimab-in-adult-participants-in-india-with-recurrent-or-advanced-endometrial-cancer-ec-100585066","NCT06897527","A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)","Phase 4, Open Label, Non-comparative, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Mismatch Repair Deficient (dMMR)\u002FMicrosatellite Instability-high (MSI-H) Recurrent or Advanced Endometrial Cancer (EC) That Has Progressed on or Following Prior Treatment With a Platinum-containing Regimen","Inclusion Criteria:\n\n* Participants ≥18 years of age, at the time of signing the informed consent.\n* Documented case of dMMR\u002FMSI-H recurrent or advanced EC that has progressed on or following prior treatment with platinum containing regimen.\n* Eligible for dostarlimab treatment according to the approved prescribing information and the investigator's clinical judgement.\n* WOCBP (Women of childbearing potential) agree to use contraceptive from screening through at least 120 days after the last dose.\n* Negative serum or urine pregnancy test at most 72 hours prior to the first dose of study medication.\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, in accordance with applicable laws.\n\nExclusion Criteria:\n\n* Known active hepatic disease, End-Stage Renal Disease (ESRD) or known case of serious, uncontrolled medical disorder\u002Factive infections which precludes participant's inclusion in the study as per the investigator's judgement.\n* Either the history of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class of the study drug.\n* Received prior therapy with an anti- programmed death receptor 1 (anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1) agent.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.\n* Received a live vaccine within 14 days of planned start of study therapy.\n* Participation in another clinical study with a study drug administered in the last 3 months.\n* Pregnant, breastfeeding, or expecting to conceive while receiving study treatment and for up to 120 days after the last dose of study treatment.\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.",{"count":57,"type":20},[59],"The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.",[26],[64,65,111,112],"dMMR","MSI-H","2025-07-04",{"date":115,"type":40},"2025-07-08",{"date":117,"type":20},"2025-07-15",{"date":119,"type":20},"2027-01-13",{"name":46,"class":47}]